Yun Ji Eun, Sull Jae Woong, Lee Hee Yeon, Park Eunjung, Kim Soriwool, Jo Jaeseong, Lee Sun Ju, Kim Sang Yeon, Choi Young Ju, Jee Sun Ha, Huh Kap Bum
Institute for Health Promotion, Graduate School of Public Health, Yonsei University, Seoul, Republic of Korea.
Diabetes Metab Res Rev. 2009 Mar;25(3):259-65. doi: 10.1002/dmrr.946.
Although adiponectin is generally known as a predictor of metabolic syndrome, potential of adiponectin as a predictor for metabolic syndrome in type 2 diabetes is debated. The purpose of this study is to determine the association between adiponectin and metabolic syndrome in patients with type 2 diabetes.
Adiponectin and the risk of metabolic syndrome were examined among 1013 type 2 diabetes patients who visited Huh's Diabetes Center from January 2003 to June 2006. Adiponectin levels were classified into quartile groups, and metabolic syndrome was defined according to the standard of National Cholesterol Education Program (NCEP) Adult Treatment Panel (ATP) III. Insulin sensitivity was directly assessed using the short insulin tolerance test (SITT) (Kitt: %/ min).
Adiponectin was significantly correlated with metabolic syndrome components. The age-adjusted correlations between adiponectin and clinical parameters including metabolic components were significant; adiponectin was negatively correlated with waist circumference, diastolic blood pressure and triglyceride, and positively correlated with high-density lipoprotein (HDL) cholesterol. Subjects with metabolic syndrome showed lower adiponectin levels than those without metabolic syndrome. After multivariate adjustment, participants with lower adiponectin levels also had a higher risk for metabolic syndrome (OR for lowest quartiles 2.21; 95% CI, 1.51-3.24). Metabolic syndrome risk was stronger among those with low adiponectin and severe insulin resistance simultaneously. This study has shown additive effects of adiponectin and insulin resistance on metabolic syndrome.
In type 2 diabetic patients, the adiponectin was a useful predictor of metabolic syndrome independent of potential confounding variables.
尽管脂联素通常被认为是代谢综合征的一个预测指标，但脂联素作为2型糖尿病患者代谢综合征预测指标的潜力仍存在争议。本研究的目的是确定2型糖尿病患者中脂联素与代谢综合征之间的关联。
对2003年1月至2006年6月期间就诊于许氏糖尿病中心的1013例2型糖尿病患者进行脂联素及代谢综合征风险检测。将脂联素水平分为四分位数组，并根据美国国家胆固醇教育计划（NCEP）成人治疗小组（ATP）III的标准定义代谢综合征。使用短胰岛素耐量试验（SITT）（Kitt：%/分钟）直接评估胰岛素敏感性。
脂联素与代谢综合征各组分显著相关。脂联素与包括代谢组分在内的临床参数之间的年龄校正相关性显著；脂联素与腰围、舒张压和甘油三酯呈负相关，与高密度脂蛋白（HDL）胆固醇呈正相关。患有代谢综合征的受试者脂联素水平低于未患代谢综合征的受试者。多因素调整后，脂联素水平较低的参与者患代谢综合征的风险也较高（最低四分位数的OR为2.21；95%CI，1.51 - 3.24）。同时存在低脂联素和严重胰岛素抵抗的患者代谢综合征风险更强。本研究显示了脂联素和胰岛素抵抗对代谢综合征的叠加作用。
在2型糖尿病患者中，脂联素是代谢综合征的一个有用预测指标，独立于潜在的混杂变量。
